{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T03:02:37Z","timestamp":1768618957214,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T00:00:00Z","timestamp":1661558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T00:00:00Z","timestamp":1661558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Bayer AG, Wuppertal, Germany"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s13318-022-00794-5","type":"journal-article","created":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T07:02:38Z","timestamp":1661583758000},"page":"803-815","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Results From Drug\u2013Drug Interaction Studies In Vitro and In Vivo Investigating the Inhibitory Effect of Finerenone on the Drug Transporters BCRP, OATP1B1, and OATP1B3"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4645-5428","authenticated-orcid":false,"given":"Roland","family":"Heinig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Fricke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Wertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Nagelschmitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Loewen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,27]]},"reference":[{"issue":"1","key":"794_CR1","doi-asserted-by":"publisher","first-page":"T125","DOI":"10.1530\/JOE-16-0600","volume":"234","author":"P Kolkhof","year":"2017","unstructured":"Kolkhof P, Baerfacker L. 30 years of the mineralocorticoid receptor: Mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol. 2017;234(1):T125\u201340.","journal-title":"J Endocrinol"},{"issue":"9","key":"794_CR2","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314(9):884\u201394.","journal-title":"JAMA"},{"issue":"31","key":"794_CR3","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, Nowack C, Kolkhof P, Kim SY, Zannad F. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453\u201363.","journal-title":"Eur Heart J"},{"issue":"23","key":"794_CR4","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"key":"794_CR5","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252\u201363.","journal-title":"N Engl J Med"},{"key":"794_CR6","unstructured":"Bayer HealthCare Pharmaceuticals Inc. KERENDIA (finerenone) tablets, for oral use: US prescribing information. 2021. https:\/\/labeling.bayerhealthcare.com. Accessed 18 Jan 2022."},{"key":"794_CR7","doi-asserted-by":"crossref","unstructured":"Lentini S, Heinig R, Kimmeskamp-Kirschbaum N, Wensing G. Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone\u2014results from first-in-man and relative bioavailability studies. Fundam Clin Pharmacol. 2016;30(2):172\u201384.","DOI":"10.1111\/fcp.12170"},{"issue":"6","key":"794_CR8","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s13318-018-0483-9","volume":"43","author":"R Heinig","year":"2018","unstructured":"Heinig R, Gerisch M, Engelen A, Nagelschmitz J, Loewen S. Pharmacokinetics of the novel, selective, non-steroidal mineralocorticoid receptor antagonist finerenone in healthy volunteers: Results from an absolute bioavailability study and drug-drug interaction studies in vitro and in vivo. Eur J Drug Metab Pharmacokinet. 2018;43(6):715\u201327.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"11","key":"794_CR9","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1124\/dmd.118.083337","volume":"46","author":"M Gerisch","year":"2018","unstructured":"Gerisch M, Heinig R, Engelen A, Lang D, Kolkhof P, Radtke M, Platzek J, Lovis K, Rohde G, Schwarz T. Biotransformation of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, in dogs, rats, and humans, in vivo and in vitro. Drug Metab Dispos. 2018;46(11):1546\u201355.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"794_CR10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s13318-020-00610-y","volume":"45","author":"R Heinig","year":"2020","unstructured":"Heinig R, Gerisch M, Bairlein M, Nagelschmitz J, Loewen S. Results from drug-drug interaction studies in vitro and in vivo investigating the effect of finerenone on the pharmacokinetics of comedications. Eur J Drug Metab Pharmacokinet. 2020;45(4):433\u201344.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"794_CR11","doi-asserted-by":"crossref","unstructured":"Rohde G, Loewen S, Heinig R. Determination of finerenone\u2014a novel, selective, nonsteroidal mineralocorticoid receptor antagonist\u2014in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study in venous and capillary human plasma. J Chromatogr B. 2021;1172:122643.","DOI":"10.1016\/j.jchromb.2021.122643"},{"key":"794_CR12","doi-asserted-by":"crossref","unstructured":"Heinig R, Nagelschmitz J, Loewen S. Results from phase I studies investigating the dose linearity of finerenone tablets and the influence of food or pH-modifying comedications on its pharmacokinetics in healthy male volunteers. Eur J Drug Metab Pharmacokinet. 2022;47(4):549\u201359.","DOI":"10.1007\/s13318-022-00770-z"},{"issue":"6","key":"794_CR13","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/cpdd.263","volume":"5","author":"R Heinig","year":"2016","unstructured":"Heinig R, Kimmeskamp-Kirschbaum N, Halabi A, Lentini S. Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94\u20138862) in individuals with renal impairment. Clin Pharmacol Drug Dev. 2016;5(6):488\u2013501.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"5","key":"794_CR14","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s13318-019-00547-x","volume":"44","author":"R Heinig","year":"2019","unstructured":"Heinig R, Lambelet M, Nagelschmitz J, Alatrach A, Halabi A. Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94\u20138862) in individuals with mild or moderate hepatic impairment. Eur J Drug Metab Pharmacokinet. 2019;44(5):619\u201328.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"3","key":"794_CR15","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40262-019-00820-x","volume":"59","author":"N Snelder","year":"2020","unstructured":"Snelder N, Heinig R, Drenth HJ, Joseph A, Kolkhof P, Lippert J, Garmann D, Ploeger B, Eissing T. Population pharmacokinetic and exposure-response analysis of finerenone: Insights based on phase IIb data and simulations to support dose selection for pivotal trials in type 2 diabetes with chronic kidney disease. Clin Pharmacokinet. 2020;59(3):359\u201370.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"794_CR16","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40262-021-01082-2","volume":"61","author":"P van den Berg","year":"2022","unstructured":"van den Berg P, Ruppert M, Mesic E, Snelder N, Seelmann A, Heinig R, Joseph A, Garmann D, Lippert J, Eissing T. Finerenone dose-exposure-response for the primary kidney outcome in FIDELIO-DKD phase III: Population pharmacokinetic and time-to-event analysis. Clin Pharmacokinet. 2022;61(3):439\u201350.","journal-title":"Clin Pharmacokinet"},{"key":"794_CR17","unstructured":"US Food & Drug Administration. Drug development and drug interactions\u2014table of substrates, inhibitors and inducers. Table 5-1. 2020. https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers#table5-1. Accessed 05 Feb 2022."},{"key":"794_CR18","unstructured":"US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Bioanalytical method validation, guidance for industry. 2018. https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf. Accessed 19 Apr 2022."},{"key":"794_CR19","unstructured":"European Medicines Agency. Guideline on bioanalytical method validation. 2011. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-bioanalytical-method-validation_en.pdf. Accessed 19 Apr 2022."},{"key":"794_CR20","unstructured":"European Medicines Agency and Committee for Human Medicinal Products (CHMP). Guideline on the investigation of drug interactions. 2012. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-drug-interactions-revision-1_en.pdf. Accessed 19 Apr 2022."},{"key":"794_CR21","unstructured":"US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). In vitro drug interaction studies\u2014Cytochrome P450 enzyme- and transporter-mediated drug interactions, guidance for industry. 2020. https:\/\/www.fda.gov\/media\/134582\/download. Accessed 19 Apr 2022."},{"issue":"15","key":"794_CR22","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1007\/s40265-021-01599-7","volume":"81","author":"JE Frampton","year":"2021","unstructured":"Frampton JE. Finerenone: first approval. Drugs. 2021;81(15):1787\u201394.","journal-title":"Drugs"},{"key":"794_CR23","unstructured":"US National Library of Medicine. Study to evaluate the efficacy (effect on disease) and safety of finerenone on morbidity (events indicating disease worsening) & mortality (death rate) in participants with heart failure and left ventricular ejection fraction (proportion of blood expelled per heart stroke) greater or equal to 40% (FINEARTS-HF). 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04435626. Accessed 5 Feb 2022."},{"issue":"12","key":"794_CR24","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1124\/dmd.120.000149","volume":"48","author":"R Sane","year":"2020","unstructured":"Sane R, Cheung KWK, Kov\u00e1cs P, Farasyn T, Li R, Bui A, Musib L, Kis E, Plise E, G\u00e1borik Z. Calibrating the in vitro-in vivo correlation for OATP-mediated drug-drug interactions with rosuvastatin using static and PBPK models. Drug Metab Dispos. 2020;48(12):1264\u201370.","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"794_CR25","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/psp4.12672","volume":"10","author":"C Costales","year":"2021","unstructured":"Costales C, Lin J, Kimoto E, Yamazaki S, Gosset JR, Rodrigues AD, Lazzaro S, West MA, West M, Varma MVS. Quantitative prediction of breast cancer resistant protein mediated drug-drug interactions using physiologically-based pharmacokinetic modeling. CPT Pharmacomet Syst Pharmacol. 2021;10(9):1018\u201331.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"10","key":"794_CR26","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/psp4.12343","volume":"7","author":"N Hanke","year":"2018","unstructured":"Hanke N, Frechen S, Moj D, Britz H, Eissing T, Wendl T, Lehr T. PBPK models for CYP3A4 and P-gp DDI prediction: a modeling network of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin. CPT Pharmacomet Syst Pharmacol. 2018;7(10):647\u201359.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"7\u20138","key":"794_CR27","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1080\/00498250802017715","volume":"38","author":"L Zhang","year":"2008","unstructured":"Zhang L, Zhang YD, Strong JM, Reynolds KS, Huang SM. A regulatory viewpoint on transporter-based drug interactions. Xenobiotica. 2008;38(7\u20138):709\u201324.","journal-title":"Xenobiotica"},{"issue":"6","key":"794_CR28","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/BF01059791","volume":"1","author":"M Rowland","year":"1973","unstructured":"Rowland M, Matin SB. Kinetics of drug-drug interactions. J Pharmacokinet Biopharm. 1973;1(6):553\u201367.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"11","key":"794_CR29","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1124\/dmd.104.000794","volume":"32","author":"JA Williams","year":"2004","unstructured":"Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi\/AUC) ratios. Drug Metab Dispos. 2004;32(11):1201\u20138.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"794_CR30","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/clpt.2012.163","volume":"92","author":"R Elsby","year":"2012","unstructured":"Elsby R, Hilgendorf C, Fenner K. Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it\u2019s not just about OATP1B1. Clin Pharmacol Ther. 2012;92(5):584\u201398.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"794_CR31","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.clpt.2004.03.010","volume":"76","author":"SG Simonson","year":"2004","unstructured":"Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, Schneck DW. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther. 2004;76(2):167\u201377.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"794_CR32","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1365-2125.2011.03972.x","volume":"72","author":"AJ Allred","year":"2011","unstructured":"Allred AJ, Bowen CJ, Park JW, Peng B, Williams DD, Wire MB, Lee E. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers. Br J Clin Pharmacol. 2011;72(2):321\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"794_CR33","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.clpt.2003.12.014","volume":"75","author":"DW Schneck","year":"2004","unstructured":"Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, Lasseter KC, Brown CD, Windass AS, Raza A. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther. 2004;75(5):455\u201363.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"794_CR34","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1124\/jpet.116.234914","volume":"358","author":"Y Lai","year":"2016","unstructured":"Lai Y, Mandlekar S, Shen H, Holenarsipur VK, Langish R, Rajanna P, Murugesan S, Gaud N, Selvam S, Date O, Cheng Y, Shipkova P, Dai J, Humphreys WG, Marathe P. Coproporphyrins in plasma and urine can be appropriate clinical biomarkers to recapitulate drug-drug interactions mediated by organic anion transporting polypeptide inhibition. J Pharmacol Exp Ther. 2016;358(3):397\u2013404.","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"794_CR35","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s40262-018-0648-3","volume":"57","author":"A Kunze","year":"2018","unstructured":"Kunze A, Ediage EN, Dillen L, Monshouwer M, Snoeys J. Clinical investigation of coproporphyrins as sensitive biomarkers to predict mild to strong OATP1B-mediated drug-drug interactions. Clin Pharmacokinet. 2018;57(12):1559\u201370.","journal-title":"Clin Pharmacokinet"},{"key":"794_CR36","unstructured":"AstraZeneca UK Limited. Crestor 10 mg film-coated tablets\u2014summary of product characteristics. 2021. https:\/\/www.medicines.org.uk\/emc\/product\/7559\/smpc. Accessed 19 Apr 2022."},{"key":"794_CR37","unstructured":"US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Clinical drug interaction studies\u2014Cytochrome P450 enzyme- and transporter-mediated drug interactions, guidance for industry. 2020. https:\/\/www.fda.gov\/media\/134581\/download. Accessed 19 Apr 2022."}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-022-00794-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-022-00794-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-022-00794-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:07:38Z","timestamp":1744715258000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-022-00794-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,27]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["794"],"URL":"https:\/\/doi.org\/10.1007\/s13318-022-00794-5","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,27]]},"assertion":[{"value":"7 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was funded by Bayer AG, Wuppertal, Germany. Editorial support, including fact checking, referencing, figure preparation, formatting, proofreading, and submission was provided by Moamen Hammad, PhD, and Ian Norton, PhD, of Scion, London, UK, supported by Bayer AG, Wuppertal, Germany, according to Good Publication Practice guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"RH, JN, RF, and SW are employees of Bayer AG. SL is an employee of Chrestos Concept GmbH & Co. KG, which received funding for this analysis from Bayer AG. In addition, RH, JN, RF, and SW have stock in Bayer AG, but are not paid in stock or stock options.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the studies before study commencement.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Availability of the data underlying this publication will be determined later according to Bayer\u2019s commitment to the EFPIA\/PhRMA principles for responsible clinical trial data sharing. This pertains to the scope, time point, and process of data access. As such, Bayer commits to sharing, upon request from qualified scientific and medical researchers, participant-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in participants for medicines and indications approved in the United States (US) and European Union (EU) as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 1, 2014. Interested researchers can use  to request access to anonymized participant-level data and supporting documents from clinical studies to conduct further research that can help advance medical science or improve patient care. Information on the Bayer criteria for listing studies and other relevant information is provided in the study sponsor\u2019s section of the portal. Data access will be granted to anonymized participant-level data, protocols, and clinical study reports after approval by an independent scientific review panel. Bayer is not involved in the decisions made by the independent review panel. Bayer will take all necessary measures to ensure that participant privacy is safeguarded.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"RH, JN, and SL participated in the study concept and design of the phase I study and were involved in the acquisition, analysis, and interpretation of the respective data. RF was involved in the study concept and design of in vitro studies, their data acquisition, and analysis. RF and SW were involved in the interpretation of the in vitro results. All authors participated in preparing the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}